According to a press release from Pfizer, Health Canada has granted a Notice of Compliance with conditions (NOC/c) to ELREXFIOTM (elranatamab solution for injection), marking its approval for use in the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM).
Elrexfio is specifically indicated for patients who have undergone at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Moreover, it is intended for individuals who have shown disease progression on their most recent treatment regimen.
The approval of Elrexfio represents a significant advancement in addressing the unmet medical needs of patients with RRMM. With its unique mechanism of action, Elrexfio offers hope for improved outcomes and quality of life. Read the full press release to learn more.